Article Text

Download PDFPDF
674 HER2 positive breast cancer management: experience of the mohammed VI centre of onco-gynecology of the IBN ROCHD university hospital of Casablanca
  1. Younes Benchrifi,
  2. Meriem Nouri,
  3. Hajar Elomri,
  4. Mustapha Benhessou,
  5. Simohamed Ennachit and
  6. Mohammed Elkarroumi
  1. CHU IBN ROCHD, Casablanca, Morocco

Abstract

Introduction/Background Breast cancer is a heterogeneous disease. However, immunohistochemistry techniques have distinguished 3 types of breast cancer: those that express hormone receptors (most common 68%), others that express the HER2 growth factor receptor (21% of cases) and the triple negative molecular type.

HER 2+ breast cancer is defined by the expression of HER2 receptors. Currently, the knowledge of its status vis-à-vis the HER2 receptor makes it possible to know if one can benefit from a targeted anti-HER2 treatment.

Methodology This is a retrospective study of a series of 443 cases of positive HER2 breast cancer collected at the Mohammed VI oncology department at the University Hospital in Casablanca between January 2019 and December 2022.

Results HER2+ breast cancer accounts for 21.1% of all breast cancers.

On the epidemic-clinical level: There was a peak of frequency between 40 and 54 years, the most frequent reason for consultation was the nodule in 80% of cases.

Anatomo-pathologically: Infiltrating ductal carcinoma is the most represented type in 97.56% of cases, with a predominance of the clinical stage T3. The histoprognostic grades SBR II and III each represent 32% and 59.3% of cases.

Therapeutically: 17.5% of patients received conservative treatment, and 82.5% underwent radical surgery such as Patey. Adjuvant chemotherapy was administered in 68.84% of cases and 26.63% received neoadjuvant chemotherapy, 67% of our patients received hormonal therapy and 95% were put on targeted therapy. While for metastatic breast cancer: of 89 cases: 87 received systemic treatment of 1st line, 31 received treatment of 2nd line, 19 (3rd line) and 10 (4th line)

Evolutionarily: 54.3% of women had good control while 22.72% developed local, locoregional and metastatic recurrences. The death rate was 12.3%.

Conclusion Our research contributes significantly to the understanding of positive HER2 breast cancer in women, highlighting factors that influence management, treatment side effects and clinical outcomes.

Disclosures Nothing to disclose.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.